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Abstract
Background: Myocardial perfusion gated single photon emission computed tomography (SPECT) can be used for
non-invasive detection of coronary artery stenosis and cardiac allograft vasculopathy (CAV), which is a crucial factor
for the long-term survival of heart transplant (HTx) recipients. A frequently observed finding in myocardial perfusion
imaging of patients after HTx is inhomogeneous myocardial perfusion. This finding is not associated with epicardial
CAV, but its prognostic relevance is unclear so far. We therefore evaluated the prognosis of patients with
homogeneous versus inhomogeneous myocardial stress perfusion.
Methods: One hundred four HTx patients (mean 3.6 ± 2.9 years after HTx) without significant stress-induced ischemia
(summed stress score ≤3) in gated SPECT and without CAV were included. Myocardial stress perfusion was visually
assessed as homogeneous, moderately, or severely inhomogeneous. The mean follow-up period after SPECT was
9.4 ± 3.1 years. End points were the diagnosis of CAV, major cardiac events (MACE) or death, and the development
of allograft dysfunction (left ventricular ejection fraction, LVEF <45 %).
Results: Of all HTx patients, 24 % enrolled in this study (n = 25) presented with inhomogeneous myocardial perfusion.
Compared to the patients with homogeneous perfusion, these patients were at higher risk for developing allograft
dysfunction (multivariate hazard ratio, HR = 5.59). As to the development of CAV, the occurrence of MACE, or death, no
statistical differences were observed between patients with homogenous and inhomogeneous perfusion. There was
no correlation between myocardial perfusion pattern and prior cardiac allograft rejections.
Conclusions: Inhomogeneous myocardial stress perfusion in SPECT studies predicts a higher risk for future development
of allograft dysfunction in HTx patients (LVEF <45 %) but is not associated with future CAV, MACE, or overall survival.
Keywords: Heart transplantation; Gated perfusion SPECT; Inhomogeneous myocardial perfusion; Cardiac allograft
vasculopathy; Ejection fraction
Background
Cardiac allograft vasculopathy (CAV) is a major compli-
cation associated with decreased long-term survival in
heart transplant recipients [1, 2]. CAV is a primary
immune-mediated process which differs from other vas-
culopathies such as coronary artery disease (CAD). The
pathophysiological process in the vessel wall in CAV
patients is characterized by a diffuse concentric intimal
proliferation affecting both the epicardial and the endocar-
dial arteries with no preferential localization [3, 4]. In the
course of the disease progressive heart failure, arrhythmia
and sudden cardiac death may occur [1]. Once severe
CAV has developed, retransplantation is the only defini-
tive treatment option [5]. Serial coronary angiography
combined with intravascular ultrasound (IVUS) is the
clinical standard for the detection of significant CAV [6].
However, non-invasive myocardial perfusion imaging
(MPI) is increasingly gaining attention as an attractive al-
ternative monitoring tool for clinically significant CAV,
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providing information on both the perfusion provided by
the main epicardial vessels and the microcirculation [7].
Although the sensitivity of MPI for the detection of CAV
is reported to be lower than for the detection of CAD [6],
several clinical studies have identified perfusion deficits
assessed by MPI as strong predictors for cardiac events in
patients after heart transplantation (HTx) [7–9]. Recent
results indicate that stress-induced ischemia and left ven-
tricular dysfunction in HTx patients assessed by gated
single photon emission computed tomography (SPECT)
correlate with prognosis [10, 11].
Apart from the presence of ischemia or scarring, a fre-
quent finding in MPI of heart transplant recipients is in-
homogeneous myocardial perfusion in angiographically
normal patients [12]. Previous studies showed that in-
homogeneous myocardial perfusion is rare within the first
year after transplantation but more frequently observed
over time [13, 14]. In a mixed cohort also including
patients with known CAV, the prevalence was up to 38 %
[11]. Interestingly, the finding is not associated with the
prevalence of CAV in angiography at the time of imaging
[13, 15]. Even when performed with IVUS, coronary angi-
ography did not detect any kind of CAV in patients pre-
senting with inhomogeneous myocardial perfusion pattern
[15]. Thus, perfusion inhomogeneity is assumed to reflect
microvasculopathy which is not detectable by angiography
[12, 15], although this hypothesis has not been proven so
far. Despite these correlative findings, the prognostic rele-
vance of inhomogeneneity in MPI of heart transplant
recipients remains unclear. Therefore, the present study
evaluates the prognostic impact of inhomogeneous myo-
cardial perfusion in heart transplant recipients without
CAV in coronary angiography.
Methods
Study population
One hundred sixty-one HTx recipients (137 males, 24
females, mean age at HTx 50.7 ± 12.2 years) undergoing
orthotopic cardiac allograft transplantation between 1990
and 2004, who underwent myocardial perfusion gated
SPECT followed by coronary angiography on a routine
basis between 04/2000 and 01/2006 at the University
Hospital Münster were identified. Patients with significant
myocardial ischemia and/or scar (summed stress score
(SSS) ≥4; n = 42), evidence of significant epicardial CAV in
coronary angiography (> 50 % stenosis; n = 33), and/or left
ventricular ejection fraction (LVEF) <45 % (n = 25) at the
start of the study were excluded. A time interval of 4 weeks
between coronary angiography and the SPECT study was
tolerated. This resulted in a total population of 104
patients.
The institutional review board of the Medical Associ-
ation of Westfalen-Lippe and the Faculty of Medicine,
University of Münster approved this retrospective study.
For the calculation of a threshold for LVEF data from an
age-matched, site-specific control group of 80 patients
with normal perfusion, a low pre-test likelihood of CAD
and without prior cardiac interventions (50 men, 30
women, mean age 50.5 ± 9.6 years; p = not statistically
significant versus HTx patients) was used. The threshold
for normal LVEF was defined as the mean value ± two
standard deviations.
Gated SPECT and image analysis
In all patients, gated SPECT was performed with 99mTc-
tetrofosmin as the perfusion agent (MYOVIEW™, Gen-
eral Electric Company, Fairfield, CT, USA). Each vial
was reconstituted with 99mTc-O4- according to the man-
ufacturer’s instructions.
All investigations were performed by a sequential stress/
rest study (1-day protocol). The stress test was performed
according to international standards by physical exercise.
The assessment of cardiac function was based on gated
SPECT data obtained under resting conditions. For the
stress study, a standard dose of about 250 MBq99mTc-
tetrofosmin was injected at peak stress while about
750 MBq were administered under resting conditions. All
patients received their standard prescribed medication
only directly after the stress test, whereas they did not take
their medication 12 h prior to the stress test.
Data acquisition started 30 to 60 min after intravenous
tracer injection (ECAM, Siemens Gammasonics; 2 heads,
24 projections, 64 × 64 matrix, 180° orbit, 50 s per step, 8
ECG-gates, zoom factor = 1.45). Flood sources were used
to obtain transmission data for attenuation correction.
Data were reconstructed into static data sets with and
without attenuation correction for perfusion analysis and,
for the rest study, into ECG-gated data sets for functional
analysis (filtered backprojection, butterworth filter, cutoff
0.6, order 5). Reconstructed images were resliced into
short axis, horizontal long axis, and vertical long axis for
clinical reading. Tracer uptake was semiquantitatively
scored for ischemia/scarring from three representative
short axis slices (apical, mid-ventricular and basal) and a
long axis slice using the 17-segment model. Each of the 17
segments was scored by two independent and experienced
observers blinded to the angiographic results according to
the ASNC guideline for semiquantitative analysis [16]. Ac-
cordingly, summed rest score (SRS), SSS, and summed
difference score (SDS) were calculated.
Left ventricular endsystolic and enddiastolic volumes
(ESV, EDV) and LVEF were calculated from the ECG-
gated SPECT data using a validated contour finding algo-
rithm (ESM, elastic surface model) [17]. Left ventricular
myocardium was segmented into 24 sectors, each 15° wide
and containing 16 small segments arranged from the apex
to the basis of each sector, resulting in 384 segments
(Fig. 1). In each case, the three outer, most basal segments
Wenning et al. EJNMMI Research  (2015) 5:51 Page 2 of 10
(n = 72) were excluded from analysis to exclude segments
with physiologically decreased uptake in the membraneous
septum. This resulted in a total of 312 small segments to
analyze. On that basis, myocardial stress and rest perfusion
was then graded into 3° of inhomogeneity (no/minimal,
moderate, and severe) by two experienced observers,
blinded to the results of the clinical follow-up as follows:
segments showing a tracer uptake of less than 70 % of the
maximum myocardial uptake were considered as patho-
logical. Cases presenting with <10 % pathologic segments
were graded as homogeneous, cases with 10–20 % patho-
logical segments were graded as moderately inhomogen-
eous, and cases showing a decreased uptake in > 20 % of
the segments were considered as severely inhomogeneous.
Pathological segments did not need to be adjacent. Since
no other reliable reference standard for the grading of
myocardial perfusion inhomogeneity exists so far, visual
grading performed by two independent observers was
used as reference. The two observers experienced in nu-
clear cardiology and blinded towards the clinical data
independently graded the degree of inhomogeneity. The
kappa values for the intra- and interobserver agreement
were 0.911 and 0.858, respectively. In single cases of dis-
agreement between the observers, a consensus was found
for final grading.
Coronary angiography
Coronary angiography was performed using the Judkins
technique [18]. Angiograms were analyzed visually by a
consensus of two experienced observers blinded to the
patient’s medical history and to the SPECT results. As
mentioned above, patients with angiographical findings
of CAV [3] were excluded from the analysis.
Echocardiography
Routine transthoracic echocardiograms (TTE) were per-
formed every 3 months from the time of SPECT imaging
by experienced cardiac sonographers according to the
guidelines of the American Society of Echocardiography
(ASE) [19]. LVEF was assessed in every patient.
Fig. 1 Short axis view of a patient presenting with inhomogeneous perfusion pattern in the stress study (upper and lower right panel). Small subsegmental
areas of perfusion impairment are marked with white arrows. Bull’s eye plot of the left ventricle for analysis of inhomogeneity (lower left panel) showing
384 subsegments arranged in 24 sectors (15°). One sector is exemplarily diagrammed
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Follow-up
Assessment of the left ventricular function in the follow-
up was performed by TTE every 3 months. Serial proto-
col coronary angiography was performed once a year to
assess the presence of epicardial CAV.
End points were defined as: manifestation of CAV in cor-
onary angiography, major cardiac event (MACE: coronary
revascularization, myocardial infarction, cardiac death or
re-transplantation), death from any cause, and the develop-
ment of allograft dysfunction (LVEF <45 %) assessed by
TTE.
Statistical analysis
Statistical analysis was performed using the SPSS software
package (IBM SPSS Statistics for Mac, Version 22.0.
Armonk, NY: IBM Corp.). Analysis of discrete variables
was performed using the chi-squared test. Comparisons of
continuous variables were performed either by a two-sided
Student’s t test for unpaired samples or by one-way analysis
of variance (ANOVA) with a Bonferroni correction applied
where appropriate. Kaplan-Meier survival curves with log-
rank tests were used for the analysis of the patient survival.
Data for patients who were lost to follow-up were cen-
sored at the time of the last contact. Univariate and multi-
variate Cox proportional hazards models were used for
estimation of hazard ratios (HR) and associated 95 %
confidence intervals (CI). A p < 0.05 was considered as
statistically significant.
Results
One hundred four patients were enrolled in the study (86
males, 18 females; mean age at MPI after HTx 52.9 ±
13.1 years, mean time after HTx 3.6 ± 2.9 years). Patients’
characteristics are shown in Table 1. The mean follow-up
time was 9.4 ± 3.1 years after MPI (median, 10.0 years;
range, 2.2–13.7 years).
Inhomogeneity
The degree of inhomogeneity was more pronounced in
the stress perfusion (Table 2). There were no cases with
inhomogeneous perfusion more pronounced in the rest
study than in the stress study. Therefore, only the degree
of inhomogeneity of the stress perfusion was further
considered. Myocardial perfusion pattern was graded as
homogeneous in 76 % of the patients (n = 79), while in-
homogeneous myocardial perfusion was present in 24 %
of the patients (n = 25), from which 19 SPECT scans
were classified as moderately inhomogeneous and 6 as
severely inhomogeneous.
Concerning the prevalence of inhomogeneous myocar-
dial perfusion, there were no significant differences be-
tween men (n = 21) and women (n = 4; p = 0.69). The
mean time after HTx at the time of imaging did not
Table 1 Patients’ characteristics
Variable All (n = 104) Homogeneous perfusion (n = 79) Inhomogeneous perfusion (n = 25) p value
Age at date of HTx (years) 49.4 ± 12.6 49.4 ± 12.6 49.4 ± 13.3 0.98
Gender (men/women) 86 (83 %)/18 (17 %) 65 (82 %)/14 (18 %) 21 (84 %)/4 (16 %) 0.46
BMI 25.8 ± 3.3 25.9 ± 3.5 25.3 ± 2.8 0.51
Reason for HTx
CAD 50 (48 %) 37 (47 %) 13 (52 %) 0.68
Dilated cardiomyopathy 44 (42 %) 35 (44 %) 9 (36 %) 0.07
Others 10 (10 %) 7 (9 %) 3 (12 %) 0.14
Systemic hypertension 88 (85 %) 65 (82 %) 23 (92 %) 0.78
Diabetes mellitus 18 (17 %) 14 (18 %) 4 (16 %) 0.68
Hypercholesterolemia 76 (73 %) 58 (73 %) 18 (72 %) 0.25
Renal failure 71 (68 %) 51 (65 %) 20 (80 %) 0.22
Malignancy 14 (13 %) 13 (16 %) 1 (4 %) 0.12
Peripheral artery disease 12 (12 %) 10 (13 %) 2 (8 %) 0.55
Beta blockers 26 (25 %) 19 (24 %) 7 (28 %) 0.55
Calcium channel antagonists 88 (85 %) 72 (91 %) 16 (64 %) 0.04
ACE inhibitors 27 (26 %) 19 (24 %) 8 (32 %) 0.39
Statins 94 (90 %) 73 (92 %) 21 (84 %) 0.77
Coronary interventions in the follow-up 15 (15 %) 13 (16 %) 2 (8 %) 0.06
MACE (incl. interventions) 20 (19 %) 15 (19 %) 5 (20 %) 0.14
Deaths in observation period 11 (11 %) 7 (9 %) 4 (16 %) 0.26
Values for age and BMI (body mass index) are expressed as mean ± standard deviation. All other data are absolute values
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differ significantly between patients with homogeneous
and inhomogeneous perfusion (3.7 ± 2.9 years versus
3.1 ± 3.0 years, p = 0.42).
In our cohort, the mean maximum predicted heart
rate (MPHR) achieved was 82.5 ± 7.8 %. Of the patients,
77.9 % (n = 81) reached a MPHR ≥85 %. Otherwise, the
exercise test was abandoned due to symptoms (angina
pectoris or dyspnea).
Semiquantitative perfusion scores are presented in
Table 3. There was no significant correlation between
the distribution of SRS or SSS between patients with
homogeneous or inhomogeneous myocardial perfusion
(p = 0.324 and p = 0.095, respectively).
The presence of significant coronary artery stenosis was
excluded in every patient. Of the 104 patients, 92 (88.5 %)
had no detectable angiographic lesion, whereas 12 patients
(11.5 %) presented with single vessel stenosis <50 %. Here,
there were no statistical differences between the preva-
lence in the homogeneous and the inhomogeneous group.
Inhomogeneous myocardial perfusion did not cor-
relate with the severity and frequency of previous
cardiac allograft rejections (p = 0.71; not shown) and
did not correlate with cardiac disease before trans-
plantation (p = 0.88; not shown).
LV function and follow-up
At the time of gated SPECT, LVEF was predominantly pre-
served but significantly lower in patients with inhomogen-
eous perfusion than in patients with homogeneous
perfusion (61.9 ± 9.2 versus 67.7 ± 7.5 %; p = 0.008) and
ESV was higher (70 ± 24 versus 54 ± 18 ml; p = 0.002;
Fig. 2a, b). EDV did not differ significantly (177 ± 37 versus
165 ± 30 ml; p = 0.11; Fig. 2c).
Although statistically not significant, data showed a
tendency of LVEF worsening with the degree of in-
homogeneity: 67 ± 8 % in patients with homogeneous
perfusion, 63 ± 9 % in patients with moderately in-
homogeneous perfusion, and 59 ± 10 % in patients with
severely inhomogeneous perfusion (p = 1.0, p = 0.29,
and p = 0.11).
In the follow-up, inhomogeneous myocardial perfusion
was associated with a significantly more frequent de-
crease of LVEF <45 % (Fig. 3a). The univariate HR was
5.0 (95 % CI, 1.52–16.4; p < 0.01; Table 4). Particularly,
the combined finding of inhomogeneous perfusion and
LVEF ≤57 % (=threshold value calculated from control
group data) in gated SPECT was associated with an in-
creased risk for the development of allograft dysfunction
(HR 3.5 [CI 1.74–6.98], p < 0.01; Fig. 3b).
In a multivariate analysis of several risk factors, only
inhomogeneous myocardial perfusion was predictive for
the development of allograft dysfunction (Table 4).
Previous cardiac allograft rejections ≥grade 2R (ISHLT
2004) were not predictive of the development of allograft
dysfunction but in contrast associated with a preserved
LV function (Table 4).
No association was found between inhomogeneous
myocardial perfusion and the manifestation of epicardial
CAV in coronary angiography in the follow-up (Fig. 4).
Moreover, no significant differences were found between
the groups with regard to the occurrence of MACE or
death of any cause in the follow-up period (Fig. 5a, b).
Immunosuppression
Of the patients, 87.5 % (n = 91) initially received a
cyclosporine-based immunosuppressive therapy, whereas
12.5 % of the patients received either everolimus (n = 1),
sirolimus (n = 2), or tacrolimus (n = 10). In the follow-
up, 36.5 % (n = 38) of the patients received a change in
immunosuppression, whereas in 26 % (n = 27) of the
cases, a change towards everolimus was performed. This
change was more frequently performed in the group
with initially inhomogeneous myocardial perfusion pat-
tern (36 versus 23 %).
Discussion
In the follow-up of heart transplantation, inhomogen-
eous perfusion is a frequent finding in myocardial perfu-
sion gated SPECT. However, its clinical significance is
Table 2 Frequency of inhomogeneous myocardial stress and
rest perfusion
Rest
Stress Inhomogeneity No Moderate Severe
No 79 0 0
Moderate 0 19 0
Severe 0 4 2
Total 79 23 2




SRS 0 40 10 50
1 20 9 29
2 18 6 24
3 1 0 1
Total 79 25 104
SSS 0 31 8 39
1 21 6 27
2 22 8 30
3 5 3 8
Total 79 25 104
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still uncertain. Only a few number of published re-
ports have analyzed myocardial perfusion inhomogen-
eity in 201Thallium myocardial SPECT of heart
transplant recipients so far [13, 15]. Here, the fre-
quency and extent of perfusion inhomogeneity was
reported to increase with time after HTx. However,
this finding did not correlate with the presence of
allograft vasculopathy as detected by coronary angiog-
raphy and IVUS [15]. Thus, perfusion inhomogeneity
in SPECT was assumed to be caused by small vessel
alterations. Despite these first important findings, the
few listed studies were either correlative or only cov-
ered a rather short follow-up time.
In this study, HTx patients had a median follow-up
of ~10 years after a first myocardial perfusion gated
SPECT in the course of heart transplantation. At the
time of SPECT imaging, patients with inhomogeneous
perfusion already had a preserved but significantly lower
LVEF in comparison to patients presenting with homoge-
neous myocardial perfusion, with a non-significant trend
of further deterioration of LVEF with a higher degree of
inhomogeneity. In the follow-up, patients with inhomo-
geneous myocardial perfusion developed left ventricular
allograft dysfunction more frequently than patients with
homogeneous myocardial perfusion. Among these pa-
tients, particularly those showing perfusion inhomogeneity
in combination with an already slightly restricted LVEF in
gated SPECT were at a higher risk for the development of
cardiac allograft dysfunction than patients with inhomo-
geneous perfusion but preserved LVEF. In a multivariate
analysis including several risk factors, only inhomogen-
eous myocardial perfusion turned out as an independent
predictor for the development of allograft dysfunction.
Surprisingly, former acute allograft rejections were associ-
ated with a preserved LV function in the follow-up. This
finding is confounding at first sight but may be explained
by a possibly more aggressive immunosuppressive therapy
in these individuals.
In non-transplanted patients, MPHR ≥ 85 % is targeted
in a physical stress test. Although MPHR is not
Fig. 2 Comparison of LVEF (a), ESV (b), and EDV (c), assessed by gated SPECT. Asterisk indicates a p value <0.01
Fig. 3 Cumulative incidence of allograft dysfunction. Comparison between patients with homogeneous and inhomogeneous perfusion (a) and
more differentiated in patients with inhomogeneous perfusion and LVEF > versus <57 % (b)
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established in the (denervated) HTx population and there-
fore may only serve as an approximate parameter for car-
diac stress in HTx patients, the targeted MPHR was
virtually achieved in our cohort. Thus, the diagnostic ac-
curacy of MPI should not be limited. In line with results
from former studies, perfusion inhomogeneity did not
correlate with the presence of epicardial CAV in coron-
ary angiography. On the other hand, the degree in-
homogeneity was more pronounced in the stress
perfusion. Thus, the results of our study support the
Table 4 Univariate and multivariate analysis of potential risk factors with regards to LV dysfunction (first row) and MACE (second
row)
Univariate analysis Multivariate analysis
Variable HR 95 % CI p value HR 95 % CI p value
Perfusion inhomogeneity No Reference Reference
Yes 5.0 1.52–16.4 0.008 5.59 1.69–18.5 0.005
3.79 0.53–26.91 0.183
ACR ≤grade 2R Reference Reference
≥grade 2R 0.18 0.04–0.81 0.025 0.16 0.34–0.73 0.018
0.27 0.03–2.57 0.253
Hypertension No Reference
Yes 0.39 0.12–1.29 0.123
0.54 0.06–5.17 0.537
PAD No Reference
Yes 1.82 0.39–8.44 0.439
2.2 0.44–11.07 0.338
Renal failure No Reference
Yes 2.96 0.64–13.57 0.164
1.74 0.180–16.87 0.632
Diabetes No Reference
Yes 1.15 0.31–4.23 0.837
0.61 0.14–2.61 0.51
Fig. 4 Cumulative incidence of epicardial CAV
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hypothesis of microvascular disease leading to inhomo-
geneous myocardial perfusion in HTx patients. Microvas-
culopathy is consecutively causing a diffuse and chronic
ischemic cardiomyopathy manifested by progressive left
ventricular dysfunction and most probably fibrosis [20].
Since no association between the SPECT perfusion pat-
tern and the frequency or severity of prior allograft rejec-
tions could be observed, a diffuse myocardial damage due
to former acute allograft rejections is unlikely to cause the
observed perfusion inhomogeneity.
Inhomogeneous myocardial perfusion in SPECT can
also be observed in non-transplanted patients with an-
giographically normal coronary arteries. Formerly often
claimed as false positive, studies suggest that endothelial
dysfunction might be the reason for the observed perfu-
sion patterns in these patients [21]. IVUS measurements
revealed that defects in myocardial perfusion scintig-
raphy correlate with occult atherosclerosis without the
presence of significant epicardial coronary artery stenosis
in angiography [22]. These results suggest that regionally
impaired myocardial perfusion reserve due to microvascu-
lar dysfunction may cause relative hypoperfusion in myo-
cardial perfusion gated SPECT. Using myocardial perfusion
positron emission computed tomography (PET), quantita-
tive perfusion abnormalities have been verified in patients
with arterial hypertension or patients with dilated and
hypertrophic cardiomyopathy without significant epicardial
coronary artery stenosis in coronary angiography, respecti-
vely—findings which underline the importance of coronary
microcirculation with regard to analysis of myocardial per-
fusion images [23]. Myocardial perfusion is also often
impaired in diabetic patients [24], and accumulating evi-
dence suggests that small vessel disease also plays a signifi-
cant role in the development of cardiac dysfunction and
the development of ‘diabetic cardiomyopathy’ [25]. That
kind of cardiomyopathy is characterized by myocardial dys-
function in the absence of coronary artery disease [26].
Most probably, microvascular dysfunction is also respon-
sible for alterations in heart function such as increased ven-
tricular wall stiffness and reduced cardiac contractility [27].
Similar to the findings in these cardiomyopathies, HTx pa-
tients enrolled in our study were free of epicardial CAV or
coronary artery disease although the pathophysiological
processes leading to CAV basically differ from those caus-
ing diabetic microangiopathy. Nevertheless, microvasculo-
pathy which is due to medial rather than endothelial
disease or a combination of both [4] is most probably re-
sponsible for the more frequent development of cardiac
allograft systolic dysfunction in HTx patients presenting
with inhomogeneous perfusion in SPECT imaging.
Although the inhomogeneous perfusion pattern was not
associated with impaired survival of the patients in our
follow-up period (≈10 years after SPECT), it has been
shown that microvasculopathy is associated with a worse
overall survival in the long-term follow-up (up to 15 years
after HTx) [4]. Recently, McArdle et al. could demonstrate
that quantitation of coronary flow reserve by dynamic PET
has an additional prognostic value in HTx patients. They
could show that patients with impaired coronary flow re-
serve were at higher risk for adverse events in a median
follow-up of about 18 months [28]. Particularly, the analysis
of coronary flow reserve in addition to the analysis of
Fig. 5 Cumulative incidence of MACE-free survival (a) and overall survival, OS (b)
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relative perfusion differences, which may miss microvascu-
lar disease, enhanced the prognostic power of myocardial
perfusion imaging. In this context, further prospective
studies using quantitative myocardial perfusion PET may
shed light on the hypothesis of microvasculopathy causing
inhomogeneity beyond the SPECT findings presented here.
Most importantly, HTx patients presenting with in-
homogeneous myocardial perfusion are at an increased
risk for the development of future allograft dysfunction.
Therefore, the analysis of inhomogeneity of myocardial
perfusion and the integration of this finding into the
clinical report can aid the management of HTx patients
in the follow-up of transplantation, although patients
may not initially present with significant myocardial is-
chemia, epicardial CAV, or signs of heart failure. The
presence of inhomogeneous perfusion could alert clini-
cians early to consider a more intensive monitoring of
left ventricular function and potential additional treat-
ments in order to prevent a further progression of
microvasculopathy and the development of progressive
allograft failure. Interestingly, despite this finding, there
were no statistically significant differences between pa-
tients with homogeneous and inhomogeneous perfusion
with regard to the occurrences of MACE or deaths. The
overall survival is generally good in the cohort, independ-
ent from the extent of perfusion inhomogeneity. A pos-
sible explanation could be the more frequent change to
everolimus in the inhomogeneous group which may have
reduced event rates. Due to the clinical setting of the
study, clinicians were aware of the imaging results. How-
ever, changes of immunosuppressive therapy were not
made depending on the grade of inhomogeneity reported.
Limitations
A limitation is given by the mixed cohort and the retro-
spective design of the study—that is not every patient
could be included from the date of HTx on, and the re-
cruitment period was long. Thus, we do not know if pa-
tients presenting with inhomogeneous perfusion in the
first SPECT studies available may have had presented
with similar perfusion patterns already at earlier time
points. On the other hand, the results should be com-
parable, since there is no difference in the mean time
interval after HTx between the analyzed groups. More-
over, the presented results may be less applicable to
women since the cohort was dominated by male
individuals.
A methodological limitation may be the grading system
for inhomogeneous myocardial perfusion pattern. The cut-
off values used for grading of inhomogeneity were defined
in comparison to visual impression of myocardial perfusion
pattern. Although the intra- and interobserver agreement
was very good, the grading system used is obviously user-
dependent and subjective by nature. Nevertheless, we think
that that kind of grading of myocardial perfusion inhomo-
geneity is reasonably feasible, apart from that there is a lack
of custom-made software for quantitation of perfusion
inhomogeneity so far. A formerly published score of in-
homogeneity [15] was not deemed suitable for the analysis,
since this method was based on 201Thallium SPECT im-
ages without attenuation correction, and the score ex-
cluded the whole inferior left ventricular wall.
Another limitation of the study is the lack of quantita-
tive data like absolute blood flow and cardiac flow reserve
which could confirm the hypothesis of microvascular dys-
function better than SPECT can do.
Conclusions
In summary, inhomogeneous myocardial stress perfusion
in gated SPECT of HTx patients is associated with a
poor prognosis concerning the development of allograft
dysfunction, defined as LVEF <45 %. On the other hand,
inhomogeneity was neither associated with the future
development of epicardial CAV nor with the occurrence
of MACE or with all cause mortality.
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